The goal of the present manuscript is to review the clinical and basic science literature to provide a current description of the cardiovascular diseases developed by lipodystrophy patients and rodent models of lipodystrophy and discuss the potential cardiovascular consequences of supplementing lipodystrophy patients chronically with leptin. This evidence concerns the gene LEP and cardiovascular disorder.